CALC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CalciMedica Inc (CALC) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock lacks positive catalysts, has bearish technical indicators, and faces significant uncertainty due to the discontinuation of its Phase 2 KOURAGE clinical trial. While some analysts see the stock as undervalued, the lack of clear growth drivers and weak financial performance make it unsuitable for long-term investment in its current state.
The technical indicators for CALC show a bearish trend. The MACD histogram is positive and expanding, which is a minor positive signal, but the RSI is neutral at 24.442, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 0.52, with resistance at 0.604. Overall, the technical setup does not indicate a strong buy opportunity.
NULL identified. The only positive note is that some analysts see the stock as oversold and undervalued, with potential in other areas like Auxora's $200M opportunity in AP.
The discontinuation of the Phase 2 KOURAGE clinical trial is a major negative catalyst, removing a key growth driver. Additionally, the stock has been downgraded by H.C. Wainwright to Neutral, citing uncertainty around safety and population clarity.
In Q3 2025, the company reported zero revenue, with a net income of -$7.8M (an improvement of 38.91% YoY). EPS increased to -0.52, up 4% YoY. Despite slight improvements, the financials remain weak, with no revenue growth and continued losses.
Analyst sentiment is mixed but leans negative. H.C. Wainwright downgraded the stock to Neutral, citing the discontinuation of the Phase 2 trial as a major concern. Oppenheimer sees the stock as oversold but acknowledges the safety concerns and trial-specific issues.
